BACKGROUND: Thyrotropin-producing @entity652 (TSHomas) account for approximately 1-2% of all @entity977 . Recently, there has been debate on primary treatment as some studies suggest a high rate of @entity4614 after transsphenoidal surgery and therefore suggest primary use of @entity1943 analogs (SSA) instead. We would like to challenge this assumption by presenting our single-center experience with transsphenoidal surgery for TSHoma. METHODS: Fifteen @entity1 treated consecutively between May 2010 and December 2016 were analyzed for long-term postoperative remission and pituitary function. RESULTS: Data on the development of TSH, fT3 and fT4 were available for 12 of 15 @entity1 (mean follow-up was 18  months, 8 @entity1   >12  months), showing mean TSH levels of 1.289  mU/l (0.02-2.04, SD 0.66), mean fT3 levels of 3.76 pmol/l (0.5-6.16, SD 1.8) and mean fT4 levels of 16.5 pmol/l (11.7-21.9, SD 3.66). Six of those @entity1 were substituted with a mean of 85.4   g  L-thyroxine after a median follow-up of 20.7  months. The other six @entity1 did not receive @entity1955 at a median follow-up of 15.5  months. One @entity1 with a known @entity5 remnant on MRI stayed euthyreotic with @entity9229 at the timepoint of follow-up 22  months after the operation. Control of the corticotrop axis was also available in 12 of 15 with no @entity1 showing a corticotroph insufficiency in the long term. CONCLUSIONS: We argue that transsphenoidal surgery for TSHoma should be considered as the treatment of choice as remission following surgery is highly probable and @entity86 is very unlikely if @entity1 are referred to centers with high pituitary surgery case loads.

Surgical treatment and outcome of TSH-producing XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity9229 :: ('MESH:C047047', 'Chemical') :: ['cabergoline'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1955 :: ('MESH:D013974', 'Chemical') :: ['L-thyroxine'] @entity4614 :: ('MESH:D007018', 'Disease') :: ['hypopituitarism'] @entity977 :: ('MESH:D010911', 'Disease') :: ['pituitary tumors'] @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative hypopituitarism'] @entity1943 :: ('MESH:D013004', 'Chemical') :: ['somatostatin'] @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas']
@entity977 :: (MESH:D010911,Disease) :: ['pituitary adenomas']
